AstraZeneca’s LogicBio Buyout Will Give Other Troubled Gene Therapy Companies Hope
Rock Bottom Prices May Tempt Big Pharma
Executive Summary
Many gene therapies companies have faced R&D and financial problems this year but the longer term potential of the field and low prices might tempt big pharma into deals.
You may also be interested in...
In Seeking ‘Strategic Alternatives’ Avrobio Is Confronting Gene Therapy Reality
Avrobio is facing up to the reality of investor skepticism about gene therapy platforms and business models – but can it find a buyer or merger partner to start again?
Bellicum Weighs Options After Hitting Brakes On CAR-T Program
An analyst suggested the company might end up selling its technology to a large pharma player, citing AstraZeneca’s $68m buyout of LogicBio in October as a precedent.
How To Turn Around A Struggling Biotech
Leaders from three companies that have managed to achieve successful turnarounds offered some advice and encouragement to biotechs weathering the current financial downturn at the recent Jefferies Healthcare conference in London.